A Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2018
At a glance
- Drugs Serlopitant (Primary)
- Indications Cough
- Focus Therapeutic Use
- Acronyms TUSSIX
- Sponsors Menlo Therapeutics
- 28 Mar 2018 According to the Menlo Therapeutics media release, data from this study is expected in the fourth quarter of 2018.
- 16 Oct 2017 Status changed from not yet recruiting to recruiting.
- 18 Sep 2017 New trial record